[1] Pape S, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. Unit Eur Gastroenterol J, 2019, 7(9): 1156-1163.
[2] Porta G, Carvalho E, Santos JL, et al. Autoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes. J Pediatr, 2019, 95(4): 419-427.
[3] Sano A, Inoue J, Kakazu E, et al. Acute-onset autoimmune hepatitis in a patient with selective immunoglobulin m deficiency. Intern Med, 2019, 58(15): 2185-2190.
[4] Honar N, Karamizadeh Z, Vazirian MV, et al. Evaluation of frequency of autoimmune hepatitis autoantibodies in children with type 1 diabetes. Rev Gastroenterol Peru, 2019, 39(4): 344-347.
[5] 李燕妮, 周璐, 张洁, 等. 自身免疫性肝病首诊特征分析: 单中心18年回顾性研究. 中华内科杂志, 2019, 58(5): 366-371.
[6] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015年). 中华肝脏病杂志, 2016, 24(1): 23-35.
[7] Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010, 51(6): 2193-2213.
[8] Czaja AJ. Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions. World J Gastroenterol, 2019, 25(45): 6579-6606.
[9] Chen J, Liu W, Zhu W. Foxp3 Treg cells are associated with pathological process of autoimmune hepatitis by activating methylation modification in autoimmune hepatitis patients. Med Sci Monit, 2019, 25: 6204-6212.
[10] Than NN, Hodson J, Schmidt-Martin D, et al. Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: results from the international autoimmune hepatitis group. J Hep Rep, 2019, 1(6): 437-445.
[11] Lu FB, Chen DZ, Chen L, et al. Attenuation of experimental autoimmune hepatitis in mice with bone mesenchymal stem cell-derived exosomes carrying microrna-223-3p. Mol Cells, 2019, 42(12): 906-918.
[12] Yu ZJ, Zhang LL, Huang TT, et al. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis. Eur J Gastroenterol Hepatol, 2019, 31(7): 873-877.
[13] Czaja AJ. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. Autoimmunity, 2019, 52(4): 144-160.
[14] Zhou J, Hu T, Gao L, et al. Friedelane-type triterpene cyclase in celastrol biosynthesis from tripterygium wilfordii and its application for triterpenes biosynthesis in yeast. New Phytol, 2019, 223(2): 722-735.
[15] Agina HA, Ehsan NA, Abd-Elaziz TA, et al. Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: relation to treatment response. Clin Exp Hepatol, 2019, 5(3): 256-264. |